Orchid Pharma Q2 Results 2026: PAT ₹29 Cr (turned profitable)
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹341Cr
- +76.3% YoY
- +12.2% QoQ
- Net profit
- ₹29Cr
- Turned profitable YoY
- +787.9% QoQ
- Margin
- 7.1%
- +7.9 pp YoY
- +2.5 pp QoQ
Guidance rank: #77 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Orchid Pharma Ltd Q2 FY27 key numbers
- Revenue
- Revenue (Net Sales) for the quarter ended September 30, 2026: Rs. 34,126.66 lakhs (both standalone and consolidated).
As stated in Orchid Pharma Ltd's Q2 FY27 results statement · published 14 Nov 2026. Reported figures, not investment advice.
Based on Orchid Pharma Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue (Net Sales) for the quarter ended September 30, 2026: Rs. 34,126.66 lakhs (both standalone and consolidated). Quarterly EBITDA: Rs. 5,816 million, up 17% year-on-year (YoY).
From Orchid Pharma Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did Orchid Pharma's revenue grow in the September 2026 quarter?
- Revenue (Net Sales) for the quarter ended September 30, 2026: Rs. 34,126.66 lakhs (both standalone and consolidated).
- Revenue for the quarter ended September 30, 2025 (revised): Rs. 29,845.86 lakhs.
- Year-on-year revenue increase: Rs. 4,280.8 lakhs (~14.3% increase).
- Other income for the quarter ended September 30, 2026: Rs. 2,863.08 lakhs (standalone), Rs. 1,775.58 lakhs (consolidated).
What happened to Orchid Pharma's margins in Q2 FY27?
Quarterly EBITDA: Rs. 5,816 million, up 17% year-on-year (YoY)
Locked: what Orchid Pharma Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Orchid Pharma planning?
- Investment in subsidiary OBPL for setting up a Jammu Manufacturing Facility: Rs. 13,500 lakhs, fully utilized by September 30, 2026.
- Capital expenditure for setting up a new block at the API Facility in Alathur, Tamil Nadu: Rs. 36 lakhs, fully utilized by September 30, 2026.
- The net proceeds from QIP raised for these purposes have been fully utilized as of September 30, 2026.
- Transfer of Synmedic Laboratories business as of July 3, 2026 through slump sale, without specified capex details.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Orchid Pharma raising money or cutting debt?
The presentation mentions a Qualified Institutional Placement (QIP) equity fundraising on June 27, 2023,…
Locked: what Orchid Pharma Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Orchid Pharma's order book?
See what Orchid Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Orchid Pharma Ltd — Quarterly revenue & net profit
Orchid Pharma Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 341 | 194 | +76.3% | 304 | +12.2% |
| Operating profit (EBITDA) | 24 | -1 | — | 14 | +72.4% |
| Operating margin | 7.1% | -0.8% | +7.9 pp | 4.6% | +2.5 pp |
| Profit before tax | 27 | -3 | — | 3 | +912.8% |
| Net profit (PAT) | 29 | -6 | — | 3 | +787.9% |
| EPS (₹) | 4.77 | -1.13 | — | 0.54 | +783.3% |
Source: Orchid Pharma Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹341 Cr, net profit ₹29 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Orchid Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Gujarat Themis Biosyn (Q2 FY27)
Standalone: ₹4,745.52 Lakhs . Key results statement takeaways from Gujarat Themis Biosyn Ltd's Q2 FY27 results statement — and how it ranks against sector peers
- Nectar Lifescience (Q2 FY27)
Quarterly EBITDA**: ₹52.7 crore, down 88% YoY . Key results statement takeaways from Nectar Lifescience Ltd's Q2 FY27 results statement — and how it ranks again
- Gufic BioScience (Q2 FY27)
288.4 crore, up from Rs. Key investor presentation takeaways from Gufic BioSciences Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q2 FY27)
Q2 FY27 Total Income:** ₹3,529.95 Lakhs, a 48.08% year-on-year (YoY) increase from Q2 FY26 (₹2,383.80 Lakhs). Key investor presentation takeaways from KRM Ayurv
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Orchid Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Orchid Pharma Ltd Q2 FY27 results?
Revenue (Net Sales) for the quarter ended September 30, 2026: Rs. 34,126.66 lakhs (both standalone and consolidated). Quarterly EBITDA: Rs. 5,816 million, up 17% year-on-year (YoY).
What is Orchid Pharma Ltd share price analysis?
Orchid Pharma Ltd currently shows a neutral. The stock trades at a P/E of 293.4 with a market cap of ₹5,300 Cr. Investors should review the full earnings analysis for detailed insights.
Is Orchid Pharma Ltd planning capital expenditure?
Investment in subsidiary OBPL for setting up a Jammu Manufacturing Facility: Rs. 13,500 lakhs, fully utilized by September 30, 2026.
Keep Orchid Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.